A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease
Launched by FERRING PHARMACEUTICALS · Jan 22, 2016
Trial Information
Current as of July 22, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Advanced prostate cancer
- • Indication to initiate androgen deprivation therapy (ADT)
- • Predefined cardiovascular disease
- Exclusion Criteria:
- • Previous or current hormonal management of prostate cancer (unless terminated at least 12 months prior to trial)
- • Acute cardiovascular disease in the previous 30 days
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a global biopharmaceutical company dedicated to the research, development, and commercialization of innovative therapies that address unmet medical needs in various therapeutic areas, including reproductive health, urology, and gastrointestinal disorders. With a strong commitment to advancing healthcare through scientific excellence and patient-centered solutions, Ferring leverages its extensive expertise in hormone-related treatments and personalized medicine. The company actively engages in clinical research to develop safe and effective therapies, striving to improve the quality of life for patients worldwide while maintaining a focus on ethical practices and collaboration in the healthcare community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Haven, Connecticut, United States
Philadelphia, Pennsylvania, United States
Durham, North Carolina, United States
Orange, California, United States
Paris, , France
Seattle, Washington, United States
Miami Beach, Florida, United States
Syracuse, New York, United States
Los Angeles, California, United States
Chattanooga, Tennessee, United States
Olomouc, , Czechia
Shreveport, Louisiana, United States
London, Ontario, Canada
Charleston, South Carolina, United States
Créteil, , France
Milwaukee, Wisconsin, United States
Cambridge, , United Kingdom
Anaheim, California, United States
Lincoln, California, United States
Tucson, Arizona, United States
Kielce, , Poland
Springfield, Illinois, United States
Denver, Colorado, United States
Nitra, , Slovakia
Burien, Washington, United States
Charleston, South Carolina, United States
Kansas City, Kansas, United States
Whittier, California, United States
Laval, Quebec, Canada
Avignon, , France
Teaneck, New Jersey, United States
Tucson, Arizona, United States
Martin, , Slovakia
Nitra, , Slovakia
Grenoble, , France
Jeffersonville, Indiana, United States
Bala Cynwyd, Pennsylvania, United States
Washington, District Of Columbia, United States
Pompano Beach, Florida, United States
Tampa, Florida, United States
Salford, , United Kingdom
Heraklion, , Greece
Torrance, California, United States
Bronx, New York, United States
Toronto, Ontario, Canada
Tucson, Arizona, United States
Scunthorpe, , United Kingdom
Jyväskylä, , Finland
La Mesa, California, United States
Lancaster, Pennsylvania, United States
Birmingham, Alabama, United States
Little Rock, Arkansas, United States
Miami, Florida, United States
Lake Barrington, Illinois, United States
Greenwood, Indiana, United States
West Des Moines, Iowa, United States
Lenexa, Kansas, United States
Towson, Maryland, United States
Mount Laurel, New Jersey, United States
Albuquerque, New Mexico, United States
Elmont, New York, United States
Salisbury, North Carolina, United States
Dayton, Ohio, United States
Middleburg Heights, Ohio, United States
Norfolk, Virginia, United States
Barrie, Ontario, Canada
Brampton, Ontario, Canada
Burlington, Ontario, Canada
Kitchener, Ontario, Canada
Oakville, Ontario, Canada
Montréal, Quebec, Canada
Québec, , Canada
Ostrava, , Czechia
Pardubice, , Czechia
Plzen, , Czechia
Praha, , Czechia
Praha, , Czechia
Příbram, , Czechia
ústí Nad Labem, , Czechia
Tampere, , Finland
Bordeaux, , France
Libourne, , France
Lille, , France
Lyon, , France
Nantes, , France
Toulouse, , France
Freiburg, Baden Wuerttemberg, Germany
Kirchheim Unter Teck, Baden Wuerttemberg, Germany
Herzogenaurach, Bayern, Germany
Braunschweig, Niedersachsen, Germany
Oldenburg, Niedersachsen, Germany
Moenchengladbach, Nordrhein Westfalen, Germany
Mülheim, Nordrhein Westfalen, Germany
Halle, Sachsen Anhalt, Germany
Lutherstadt Eisleben, Sachsen Anhalt, Germany
Dresden, Sachsen, Germany
Leipzig, Sachsen, Germany
Bonn, , Germany
Athens, , Greece
Athens, , Greece
Athens, , Greece
Patras, , Greece
Thessaloníki, , Greece
Piotrków Trybunalski, , Poland
Wrocław, , Poland
łódź, , Poland
Ekaterinburg, , Russian Federation
Moscow, , Russian Federation
Moscow, , Russian Federation
Moscow, , Russian Federation
Moscow, , Russian Federation
Nizhniy Novgorod, , Russian Federation
Novosibirsk, , Russian Federation
Omsk, , Russian Federation
Saint Petersburg, , Russian Federation
Bratislava, , Slovakia
Bratislava, , Slovakia
Kosice, , Slovakia
Košice, , Slovakia
Košice, , Slovakia
Levice, , Slovakia
Liptovský Mikuláš, , Slovakia
Prešov, , Slovakia
Rimavska Sobota, , Slovakia
Sala, , Slovakia
Trenčín, , Slovakia
žilina, , Slovakia
Cape Town, Western Cape, South Africa
Llanelli, Carmarthenshire, United Kingdom
London, Greater London, United Kingdom
Chertsey, Surrey, United Kingdom
Sheffield, West Midlands, United Kingdom
Exeter, , United Kingdom
Scunthorpe, Lincolnshire, United Kingdom
Patients applied
Trial Officials
Global Clinical Compliance
Study Director
Ferring Pharmaceuticals
Susan Slovin, MD
Principal Investigator
Sidney Kimmel Center for Urologic and Prostate Cancers, Memorial Sloan Kettering Cancer Center
John Alexander, MD, MHS
Principal Investigator
Division of Cardiovascular Medicine, Duke Clinical Research Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials